GS002

GS002 (also designated 002mAb-GSLP003) is an investigational anti-PD-L1 antibody-drug conjugate (ADC) developed by Shanghai Ginspire Biologics. It comprises a high-affinity, Fc-silent IgG1κ antibody engineered to promote endocytosis, site-specifically conjugated via a solubility-enhanced linker to a novel topoisomerase I inhibitor payload with a drug-to-antibody ratio (DAR) of 8. GS002 exhibits a dual mechanism of action, combining potent PD-L1-targeted cytotoxicity with immune checkpoint blockade. Preclinical data demonstrate that GS002 induces potent cytotoxicity in PD-L1-positive tumor cells and exhibits sustained antitumor activity across multiple xenograft models, matching or exceeding the efficacy of competitor ADCs. The molecule shows high plasma stability and a favorable pharmacokinetic profile, supporting its advancement into IND-enabling development for the treatment of cancer.